Long COVID Prevention: Vaccine Effectiveness in Pediatric Populations
1 Wu et al. 2024 β BNT162b2 Effectiveness Against Long COVID in Children and Adolescents
Full Citation:: Wu Q, Zhang B, Tong J, et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. EClinicalMedicine. 2024;79:102962. (Wu et al. 2024) DOI:: 10.1016/j.eclinm.2024.102962 PMID:: 39720603 / PMCID: PMC11667630 Study Design:: Real-world comparative effectiveness; EHR data from 385,000+ children across 13 hospitals; Delta and Omicron cohorts; causal mediation analysis (RECOVER consortium) Key Findings::
- BNT162b2 was 95.4% effective against long COVID in adolescents during Delta; 75.1% (adolescents) and 60.2% (children) during Omicron
- Causal mediation analysis: vaccine effectiveness operates primarily via reducing acute infection risk, not through direct post-infection immune modification
- Large real-world sample ($n>385{,}000$) across diverse hospital systems strengthens generalisabilityRelevance:: Relevant to the post-viral ME/CFS in children section. Demonstrates that preventing acute SARS-CoV-2 infection in children substantially reduces long COVID incidence β supporting the model that long COVID (and by extension post-COVID ME/CFS) arises from the infection process itself, not just pre-existing vulnerability. The mediation finding (vaccine works via infection prevention, not post-infection) has implications for understanding why post-exposure interventions are harder. Certainty Assessment::
- *Quality:* High (EClinicalMedicine/Lancet; large multi-site EHR study; causal mediation)
- *Sample:* $n > 385{,}000$ children across 13 hospital systems
- *Replication:* Consistent with other vaccine-Long COVID effectiveness studies
- *Certainty:* 0.80
- *Limitation:* Effectiveness wanes with Omicron variant; mediation analysis relies on correct model specification